Deciphera Pharmaceuticals Stock News

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the last trading session, 1.13 million shares of the Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) were traded, and its beta was 1.55. Most recently the company’s share price was $7.08, and it changed around $0.21 or 3.06% from the last close, which brings the market valuation of the company to $439.95M. DCPH currently trades at a … Why Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Is A Stock Not To Be Discarded In 2022 Read More »

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of t

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) price closed lower on Monday, February 28, dropping -4.58% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $8.08, with intraday deals fluctuated between $7.3804 and $8.08. … Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Is Down -4.58% – Can It Revive? Read More »

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared to $0.69 from the ye

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter -

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript

Deciphera Pharmaceuticals press release (DCPH): Q4 GAAP EPS of -$1.51 misses by $0.03.Revenue of $24.2M (+24.2% Y/Y) beats by $0.92M.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected result

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for